Trial data suggest pain reduction exceeding 30% in approximately 50–65% of treated participants. However, CRPS exhibits marked placebo and natural variability effects, and no blinded sham-controlled trials with more than 50 participants have been completed. Real-world outcomes from uncontrolled clinics report higher perceived success rates (70–80%), though selection bias and loss-to-follow-up are substantial. Published efficacy evidence remains modest.
Two registered clinical trials are actively investigating stem cell interventions in CRPS populations. One multicentre trial examined intravenous allogeneic placental MSCs in 34 CRPS patients; preliminary results reported pain reduction (measured on 0–100 numerical rating scale) averaging 28–32 points at 12 weeks, compared to 8–12 points in sham controls. A second smaller trial of neurogenic precursor cells showed subjective functional improvement in hand dexterity tasks. Neither trial has reported long-term follow-up beyond 6 months. No major efficacy data have been published in peer-reviewed journals. Mechanistic research continues.
Sunt un candidat? → · Complex Regional Pain Syndrome: full overview → · Cost Sindromul Durerii Regionale Complexe → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită